share_log

CB Scientific, Inc. Enters Regulatory Testing Phase for Updated myCam Cardiac Event Monitoring Device

CB Scientific, Inc. Enters Regulatory Testing Phase for Updated myCam Cardiac Event Monitoring Device

CB Science,Inc.进入最新MyCam心脏事件监测设备的监管测试阶段
Accesswire ·  2022/05/24 18:05

Enhanced product to include significant operating enhancements and material design advances over the current offering

与当前产品相比,增强的产品包括显著的运营增强和材料设计改进

ESCONDIDO, CA / ACCESSWIRE / May 24, 2022 / CB Scientific. Inc. (OTCQB:CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products and services, today announced that it has entered the regulatory testing phase for its updated myCam cardiac event monitoring device. Regulatory testing not only demonstrates the myCam product's safety and efficacy but also represents an important milestone towards the company's efforts to obtain 510(k) "Clearance to Market" for the device from the United States Food and Drug Administration (FDA).

加利福尼亚州埃斯孔迪多/ACCESSWIRE/2022年5月24日/CB Science。非侵入性动态心脏监测产品和服务的设计商、制造商和分销商CBSC(场外交易市场代码:CBSC)(“CBSC”或“公司”)今天宣布,其最新的myCam心脏事件监测设备已进入监管测试阶段。监管测试不仅证明了myCam产品的安全性和有效性,还代表着该公司努力使该设备获得美国食品和药物管理局(FDA)的510(K)“上市许可”的一个重要里程碑。

"The enhanced design of our new myCam product provides improved power consumption, enhanced lead wire shielding, superior signal quality, and more cost-effective part sourcing," said Charles Martin, Chief Executive Officer of CB Scientific, Inc. "While this latest myCam product design maintains all of the core functionality our previous state-of-the-art auto-trigger device offers, it will most definitely better position the Company to compete effectively in the market going forward."

CB Science,Inc.首席执行官查尔斯·马丁说:“我们新MyCam产品的改进设计提供了更高的功耗、更好的引线屏蔽、更高的信号质量和更具成本效益的部件采购。虽然最新的MyCam产品设计保持了我们以前最先进的自动触发设备提供的所有核心功能,但它肯定会使公司在未来的市场中更有效地竞争。“

The company anticipates the new myCam 510(k) submission will take place in the coming weeks, and once it receives regulatory clearance from the FDA the company expects to produce and deliver the product both domestically and internationally to markets such as Asia, Latin America, and the Middle East, each of which requires FDA certification.

该公司预计,新的myCam 510(K)将在未来几周内提交,一旦获得FDA的监管批准,该公司预计将在国内和国际上生产并向亚洲、拉丁美洲和中东等市场交付产品,这些市场中的每一个都需要FDA认证。

As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.

随着更多新情况的出现,CB Science,Inc.计划通过新闻稿和监管文件及时发布公告,让其股东、行业参与者和公开市场了解情况。

About CB Scientific, Inc.

关于CB Science,Inc.

CB Scientific, Inc., through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.

CB Science,Inc.通过其国内和国际子公司,在动态非侵入性心脏监测领域提供创新的产品和服务。我们的FDA和CE批准的EKG设备、基于云的交互式采集软件和适用于iOS和Android平台的智能手机应用程序为有异常心律风险的患者提供了更好的遵从性,并为医生提供了更准确的信息。

Company Contact Information:

公司联系信息:

Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: Robert Hesse - dorchco.bh@gmail.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter

电话:(888)225-0870
电子邮件:General Query:Info@cbScience ficinc.com
投资者咨询:Robert Hesse-dorchco.bh@gmail.com
关注CBSC:Twitter、Facebook、Instagram、LinkedIn、YouTube和时事通讯

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.

这一信息披露可能包含《1995年私人证券诉讼法案》所涵盖的前瞻性陈述。这些前瞻性陈述涉及推出或增强我们的服务和产品的计划和时间,有关未来市场状况、供需状况的陈述,以及本新闻稿中包含的其他预期、意图和计划,这些都不是历史事实,涉及风险和不确定性。我们对未来收入的预期取决于我们开发和提供产品和服务的能力,这些产品和服务可能不是我们今天生产的,而且符合规定的规格。在本新闻稿中使用的“计划”、“预期”、“相信”以及类似的表述通常代表前瞻性陈述。这些声明反映了我们目前的预期。它们受到许多风险和不确定性的影响,包括但不限于技术的变化和普遍存在的市场的变化。本新闻稿包括1933年《证券法》第27A节和1934年《证券法》第27E节所指的前瞻性陈述。本新闻稿中包含的非历史事实的陈述可能被视为前瞻性陈述。请投资者注意,前瞻性陈述本质上是不确定的。由于某些风险和不确定因素,包括但不限于获得融资以及监管机构和股东对预期行动的批准的能力,实际业绩和结果可能与本文预测或建议的情况大不相同。

SOURCE: CB Scientific, Inc.

资料来源:CB Science,Inc.


View source version on accesswire.com:
在accesswire.com上查看源代码版本:

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发